New muscle for failing hearts
Up to 1 billion heart muscle cells may die as a result of reduced blood supply during a heart attack. This can lead to debilitating and often fatal heart failure. Our researchers in collaboration with Swedish biotech company, Procella Therapeutics and the Karolinska Institute, are determined to change that. We plan to fully investigate formation of ventricular cardiomyocytes following HVP cell therapy. We want to know how these cells integrate with muscle cells already in the heart, and how they affect tissue regeneration and cardiac function. ------------------------------------------------------------ Global site: https://www.astrazeneca.com/ Careers site: https://careers.astrazeneca.com/ Follow us: Twitter: / astrazeneca LinkedIn: / astrazeneca Instagram: / astrazeneca Facebook: / astrazeneca

Progenitor cells regenerate heart muscle and repel scar-forming fibroblasts

EBUS guide for interventional bronchoscopists

The potential of T-cell receptor therapies

Title: Global Operations at AstraZeneca – Change a Life

The Discovery Centre (DISC): Unlocking the power of science

In Vivo Cell Therapy

Early Talent at AstraZeneca: Shaping the Future Together

Living with Blood Cancer: Tania’s Story

Combining CRISPR and AI to accelerate cancer drug discovery

Cell therapy uncovered: advancing cell therapy in the clinic

EBUS guide for patients: bronchoscopy technique for chest abnormalities

The AstraZeneca story

Realising the Full Curative Potential of Cell Therapy

Full-Year 2025 Results

AstraZeneca IT – Follow the Sun

AI and the Big Difference in Health Care

Global Procurement. Speed, Savings, Sustainability

Living With Obesity: Nicci’s Journey

Epigenetics: the next revolution in cancer treatments

